针对瘤细胞表面受体的蛋白质溶解向嵌合体 (PROTAC) 驱动的抗体内部化
Ezequiel J Tolosa1, Lin Yang1, Jennifer Ayers-Ringler1
1Mayo Clinic, Rochester, MN, USA.
Communications biology
|December 31, 2024
概括
蛋白质溶解向嵌合体 (PROTACs) 通过诱导强制细胞吸收来增强抗体-药物结合体 (ADC) 的内化和有效性. 这种组合策略显示出改善癌症治疗结果的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗体-药物合物 (ADC) 提供细胞毒性有效载荷,但依赖于细胞内化以获得有效性.
- 在目标结合时,ADC的内部化并未得到保证,这限制了它们的治疗潜力.
- 针对蛋白质分解的嵌合体 (PROTACs) 正在成为诱导蛋白质降解和细胞事件的工具.
研究的目的:
- 调查PROTACs是否可以增强ADC内部化和活动.
- 探索 PROTACs 可能改善 ADC 功能的机制.
- 为在临床环境中结合PROTACs和ADCs提供一个理由.
主要方法:
- 使用针对细胞表面蛋白质 (EGFR,HER2,MET) 的PROTAC与ADC或抗体一起使用.
- 在各种模型中,具有和没有PROTAC的ADC/抗体的量化内部化率.
- 评估HER2-向ADCs与PROTACs结合的细胞毒性.
- 研究了动氨酸和蛋白质溶解在PROTAC介导增强中的作用.
主要成果:
- 在共同向EGFR,HER2或MET时,PROTACs增加了抗体和ADC的内部化1.4-1.9倍.
- PROTACs显著增强了针对HER2的ADCs的细胞毒性.
- 观察到的效应取决于动氨酸介导的内细胞和蛋白质分解.
结论:
- PROTACs可以显著改善ADC内部化,并增强其细胞毒性活性.
- 这种PROTAC介导的ADC增强依赖于特定的细胞机制.
- 结合PROTACs和ADCs是改善癌症治疗的有希望的策略,需要进行临床研究.
相关概念视频
Receptor-mediated Endocytosis
5.8K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
5.8K
Receptor Tyrosine Kinases
11.6K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
11.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
Cancer Cell Migration through Invadopodia
2.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.2K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K


